

# Eicosanoids & Platelet Activating Factor


**Prof. Sanjay Khattri**

**Dept. of Pharmacology & Therapeutics**

**King George's Medical University, Lucknow**

# Autacoid

- These are the substances produced by wide variety of cells that act locally at the site of production. (local hormones)



# Mediators of Inflammation and Immune reaction

1. Vasoactive amines (Histamine and Serotonin)
2. Eicosanoids
3. Platelet Activating Factor
4. Bradykinins
4. Nitric Oxide
5. Neuropeptides
6. Cytokines

# EICOSANOIDS

- PGs, TXs and LTs are all derived from **eicosa** (referring to 20 C atoms) **tri/tetra/ penta enoic acids**. Therefore, they can be collectively called *eicosanoids*.
- Major source: **5,8,11,14 eicosa tetraenoic acid (arachidonic acid)**.
- Other eicosanoids of increasing interest are: lipoxins and resolvins.
- The term **prostanoid** encompasses both **prostaglandins and thromboxanes**.

## EICOSANOIDS Contd....


- In most instances, the initial and **rate-limiting step** in eicosanoid synthesis is the **liberation of intracellular arachidonate**, usually in a one-step process catalyzed **by the enzyme phospholipase A<sub>2</sub> (PLA<sub>2</sub>)**.
- PLA<sub>2</sub> generates not only arachidonic acid **but also lysoglyceryl - phosphorylcholine (lyso-PAF)**, the precursor of platelet activating factor (PAF).

# EICOSANOIDS Contd....

Corticosteroids inhibit the enzyme  $PLA_2$  by inducing the production of lipocortins (annexins).


The free arachidonic acid is metabolised separately (or sometimes jointly) by several pathways, including the following:

- **Cyclo-oxygenase (COX)**- Two main isoforms exist, COX-1 and COX-2
- **Lipoxygenases**- Several subtypes, which often work sequentially, synthesise leukotrienes.



Summary diagram of the inflammatory mediators derived from phospholipids, with an outline of their actions and the sites of action of anti-inflammatory drugs.

# Cell Membrane Phospholipids






# CYCLOOXYGENASES

COX-1	COX-2	COX-3
<ul style="list-style-type: none"><li>•Constitutive (always present in cells)</li><li>•Serves house-keeping function e.g. gastroprotective</li></ul>	<ul style="list-style-type: none"><li>•Inducible (synthesis stimulated by endotoxins and other inflammatory mediators)</li><li>•Participates in inflammation</li><li>•Constitutive in brain, endothelium and kidney</li><li>•Procarcinogenic</li></ul>	<ul style="list-style-type: none"><li>•Recently isolated from cerebral cortex</li><li>•Involved in pain perception and fever</li><li>•Not involved in inflammation</li><li>•Paracetamol targets COX-3</li></ul>

# Differential Actions of Cyclooxygenases



# Pathophysiological Roles

## CNS

- PGE<sub>1</sub> and PGE<sub>2</sub> are pyrogenic and cause fever.
- NSAIDs act as antipyretic agents by inhibiting these PGs.

## Peripheral Nerve Endings

- PGE<sub>2</sub> and PGI<sub>2</sub> sensitize pain receptors to various mediators.
- NSAIDs act as analgesics by decreasing the synthesis of PGs.

# Pathophysiological Roles

## CVS

- $\text{PGE}_2$ ,  $\text{PGI}_2$  are vasodilators whereas  $\text{TXA}_2$  are vasoconstrictor agents.
- $\text{PGI}_2$  is used in pulmonary hypertension
- $\text{PGE}_2$  increases capillary permeability.
- $\text{PGE}_2$  and  $\text{PGI}_2$  keeps ductus arteriosus patent.

## PLATELETS

- $\text{PGI}_2$  inhibits platelet aggregation whereas  $\text{TXA}_2$  is a potent aggregator of platelets.
- $\text{PGI}_2$  can be used as an anti-aggregatory drug in dialysis and cardiopulmonary bypass, storage of platelets for transfusion.

## Pathophysiological Roles

### PLATELETS Contd...

- Thromboxane A<sub>2</sub> stimulates blood platelet aggregation, essential to the role of platelets in blood clotting.

### UTERUS

- PGE<sub>2</sub> and PGF<sub>2α</sub> are powerful uterine stimulants (contraction) and cervical ripening
- PGs are responsible for pain during menstruation and NSAIDs like mefenamic acid are useful for relieving this pain.

# Pathophysiological Roles

## BRONCHUS

- $\text{PGE}_2$  and  $\text{PGI}_2$  are bronchodilators and  $\text{PGF}_{2\alpha}$  &  $\text{TXA}_2$  are bronchoconstrictor agents.
- Aerosolized  $\text{PGE}_2$  has been used effectively to abort acute attacks of asthma.
- COX inhibitors like aspirin causes more production of LTs.
- Aspirin can result in participation of asthma attacks because LTs are the main bronchoconstricting mediators in human asthma.

# Pathophysiological Roles

## GIT

- PGE<sub>2</sub> and PGI<sub>2</sub> decreases acid secretion and increases mucus production and mucosal blood flow.
- All these factors decrease the chances of peptic ulcer.
- PGE<sub>2</sub>, PGF<sub>2α</sub> : Spasmogenic, ↑ fluid & electrolyte secretion.

## KIDNEY

- PGE<sub>2</sub> and PGI<sub>2</sub> causes renal vasodilation, natriuresis and increased water clearance due to inhibition of the action of ADH. These agents also facilitate renin release.

## EYE

- PGF<sub>2α</sub> decreases intraocular pressure by increasing the uveoscleral outflow.

# Clinical Uses

## CVS:

- *Epoprostenol (PGI<sub>2</sub>) and treprostinil (longer acting PGI<sub>2</sub> analogue) can be used for the treatment of pulmonary hypertension.*
- **To keep ductus arteriosus patent** before surgery : *alprostadil (PGE<sub>1</sub>) and **epoprostenol** (PGI<sub>2</sub>)*
- **Patent Ductus Arteriosus (PDA)** at birth, *NSAIDs like aspirin and **indomethacin*** are given to close it.



## Platelets:

- *Low dose aspirin* can be used as an *antiplatelet* drug for the prophylaxis of MI and stroke.
- *Epoprostenol* (PGI<sub>2</sub>) can be used as an *anti-aggregatory drug in dialysis and cardiopulmonary bypass*. It can also be used for storage of platelets for transfusion.

## UTERUS:

- Dinoprostone ( $\text{PGE}_2$ ) intravaginally and carboprost (*15-methyl  $\text{PGF}_2\alpha$* ) intraamniotic injection can be used for inducing mid trimester abortion.
- Misoprostol ( $\text{PGE}_1$ ) along with methotrexate or mifepristone is used for induction of abortion in first few weeks of pregnancy.
- *Dinoprostone or misoprostol* intravaginally are employed for *cervical ripening during labour*.
- *Carboprost (15-methyl  $\text{PGF}_2\alpha$ )* can be used to control *post partum hemorrhage* (contraction of uterus leads to compression of blood vessels resulting in decreased bleeding).

## Bronchus:

- *Aerosolized PGE2* has been used effectively *to abort acute attacks of asthma.*
- COX inhibitors like aspirin cause more production of LTs (because due to enzyme inhibition arachidonic acid now produces only LTs).
- *Aspirin can result in precipitation of asthma attacks*

## GIT

- NSAIDs on long term use can precipitate PUD due to inhibition of PG synthesis.
- *Misoprostol is the most specific drug for the treatment of peptic ulcer due to chronic NSAID use. [The drug of choice is proton pump inhibitors]*
- PG seems to play some role in colonic cancer. *Regular use of aspirin or celecoxib decreases the risk of colonic polyps and cancers.*

## KIDNEY

- Loop diuretics act partly by increasing the stimulation of COX; therefore *NSAIDs attenuate the diuretic action* of these drugs.
- **Bartter syndrome** is characterized by *excess PGs* leading to *hyperreninemia, excess aldosterone and the resultant hypokalemia and alkalosis*.
- **Indomethacin** is used for *treatment* of this syndrome.

## Male reproductive system

- PGE2 and PGI2 increases sperm motility and enhances penile erection.
- *Alprostadil can be used to treat erectile dysfunction.*

## EYE

- PGF2 $\alpha$  decreases intraocular pressure by **increasing the uveoscleral outflow.**
- Latanoprost (PGF2 $\alpha$ ) is being used as eye drops for glaucoma.
- *Bimatoprost, travaprost and unoprostone are new prostaglandin analogues for this indication.*

1. *PGI<sub>2</sub> analogue- Epoprostenol and Treprostinil*

2. *PGE<sub>1</sub> analogue- alprostadil, Misoprostol*

3. *PGE<sub>2</sub> analogue- Dinoprostone*

4. *PGF<sub>2</sub>α analogue- Carboprost*

*Latanoprost, Bimatoprost, travaprost and unoprostone*



# LEUKOTRIENES

- Leukotrienes are synthesised from arachidonic acid by lipoxygenase-catalysed pathways.
- These soluble cytosolic enzymes are mainly found in lung, platelets, mast cells and white blood cells. The main enzyme in this group is 5-lipoxygenase.
- The 5-lipoxygenase forms 5-hydroperoxytetraenoic acid (5-HPETE), leading to the production of the unstable leukotriene (LT) $A_4$ .
- This may be converted enzymatically to  $LTB_4$  and utilising a separate pathway to the cysteinyl leukotrienes  $LTC_4$ ,  $LTD_4$ ,  $LTE_4$ .

## Leukotrienes cont....

- **LTB<sub>4</sub>**, acting on specific receptors, causes adherence, chemotaxis and activation of polymorphs and monocytes, and stimulates proliferation and cytokine production from macrophages and lymphocytes.
- LTB<sub>4</sub> is an important mediator in all types of inflammation; the cysteinyl leukotrienes are of particular importance in asthma.
- The **cysteinyl leukotrienes** cause: – contraction of bronchial muscle – vasodilatation in most vessels, but coronary vasoconstriction.

# Leukotrienes contd....

- **Leukotrienes** have roles in **inflammation**.
- They are produced in areas of inflammation in blood vessel walls as part of the pathology of **atherosclerosis**.
- Leukotrienes are also implicated in **asthmatic** constriction of the bronchioles.

## Action of LT s can be inhibited by:

- *Corticosteroids* (decrease the production of LTs by inhibiting phospholipase A2)
- Lipoxxygenase inhibitors (*zileuton*)
- LT receptor antagonists (*zafirlukast, montelukast, iralukast*)

# PLATELET-ACTIVATING FACTOR

- Platelet-activating factor is a biologically active lipid that can produce effects at exceedingly low concentrations (Gq/G<sub>11</sub>; stimulates cAMP production).
- PAF is believed to be an important mediator in both **acute and chronic allergic and inflammatory phenomena**.
- PAF is produced by platelets in response to thrombin, and by activated inflammatory cells.
- **Rupatidine** is a combined H<sub>1</sub> and PAF antagonist that is used for treating allergic symptoms
- **Lexipafant** (PAF antagonist) is in clinical trial in the treatment of acute pancreatitis.

# LIPOXINS

- Lipoxins are formed by the concerted action of the 5- and the 12- or 15-lipoxygenase enzymes during inflammation.
- Lipoxins act on polymorphonuclear leukocytes, through a distinct G protein-coupled receptor system to oppose the action of pro-inflammatory stimuli, supplying what might be called 'stop signals' to inflammation.
- Aspirin (a COX inhibitor) stimulates the synthesis of lipoxins.

**THANK YOU**